Neurocrine Biosciences Inc NBIX:NASDAQ

Last Price$75.10NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$72.00 (10)
Ask (Size)$75.10 (61)
Day Low / HighN/A - N/A
Volume1.2 M

View Biotechnology IndustryPeer Comparison as of 01/21/2022


Neurocrine Biosciences Inc ( NASDAQ )

Price: $75.10
Change: +2.30 (3.16%)
Volume: 1.2 M
4:00PM ET 1/21/2022

Novavax Inc ( NASDAQ )

Price: $84.65
Change: -5.71 (6.32%)
Volume: 5.8 M
4:00PM ET 1/21/2022

Mirati Therapeutics Inc ( NASDAQ )

Price: $114.03
Change: -4.31 (3.64%)
Volume: 595.4 K
4:00PM ET 1/21/2022

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Intellia Therapeutics Inc ( NASDAQ )

Price: $81.52
Change: -1.10 (1.33%)
Volume: 1.4 M
4:00PM ET 1/21/2022

Read more news Recent News

Barclays Adjusts Neurocrine Biosciences Price Target to $100 From $110, Maintains Overweight Rating
12:20PM ET 1/20/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average rating of Outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....

Neurocrine Biosciences Shares Drop After RBC Downgrade
2:27PM ET 1/18/2022 MT Newswires

Neurocrine Biosciences (NBIX) shares were down 4% in Tuesday afternoon trading after RBC downgraded the biopharmaceutical company's stock to sector perform...

RBC Downgrades Neurocrine Biosciences to Sector Perform From Outperform, Sees 2022 as 'Investment Year' With Fewer Upside Catalysts, Cuts Price Target to $90 From $122
8:58AM ET 1/18/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $76 to...

Xenon Pharmaceuticals Says Partner Neurocrine Biosciences Hits Regulatory Milestone in Epilepsy Collaboration
9:01AM ET 1/12/2022 MT Newswires

Xenon Pharmaceuticals (XENE) said Wednesday said it was set to receive a payment of $15 million from its epilepsy joint venture partner Neurocrine...

Company Profile

Business DescriptionNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA. View company web site for more details
Address12780 El Camino Real
San Diego, California 92130
Number of Employees585
Recent SEC Filing01/18/2022CT ORDER
Chief Executive Officer & DirectorKevin Charles Gorman
Vice President-Information Technology & OperationsBill Wilson
Chief Financial OfficerMatthew C. Abernethy
Chief Research OfficerDimitri E. Grigoriadis

Company Highlights

Price Open$72.94
Previous Close$72.80
52 Week Range$71.88 - 120.27
Market Capitalization$7.1 B
Shares Outstanding94.9 M
SectorHealth Technology
Next Earnings Announcement02/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings16.43
Earnings per Share$4.83
Beta vs. S&P 500N/A
Revenue$451.2 M
Net Profit Margin41.59%
Return on Equity35.89%

Analyst Ratings as of 01/19/2022

Consensus RecommendationConsensus Icon
Powered by Factset